Depomed (DEPO) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy
May 9, 2016 7:37 AM EDTMizuho Securities upgraded DepoMed Inc (NASDAQ: DEPO) from Neutral to Buy with a price target of $19.00 (from $18.00), on increased takeout probability.
Analyst Irina Koffler commented, "DEPO posted unimpressive numbers in 1Q:16 and shares got dragged down with the group on Friday.... More
DepoMed (DEPO) PT Lowered to $21 at Piper Jaffray
May 6, 2016 9:09 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on DepoMed Inc (NASDAQ: DEPO) to $21.00 (from $23.00) and reiterated a Overweight rating following Q1 results.
Amsellem commented, "Depomed reported adjusted diluted EPS of $0.12 on revenues of $105M, versus Street estimates of $0.17 and $107M, respectively... More



